Background {#Sec1}
==========

Dyslipidemia is one of the major risk factor for establishing coronary artery disease (CAD) \[[@CR1]\]. Coronary artery disease and cerebral stroke account for the main causes of morbidity and mortality among elderly and middle-aged individuals \[[@CR2]\]. Cardiovascular risk factors are including aging, hyperglycemia and insulin resistance \[[@CR3]\]. In addition, dyslipidemia, mainly hypercholesterolemia, high LDL-cholesterol, and low HDL-cholesterol levels \[[@CR4]\] impair mitochondrial function, leading to increased production of free radicals and reactive oxygen species, and subsequently can result in chronic inflammation and endothelial dysfunction \[[@CR5]\].

The damage of free radicals is proposed to play an important role in endothelial dysfunction and atherogenesis \[[@CR6]\]. Coenzyme Q10 (CoQ10) is an intracellular antioxidant which prevents senescence and dysfunction caused by oxidative stress \[[@CR6]\]. CoQ10 is commonly used to treat cardiomyopathy, and heart function has been remarkably improved following CoQ10 supplementation \[[@CR7]\]. CoQ10 deficiency which usually occurs with aging have been shown to increase the risk of type 2 diabetes mellitus (T2DM) \[[@CR8]\] and cardiovascular disease (CVD) \[[@CR9]\]. On the other hand, there are trials evaluating the effects of CoQ10 on lipid profiles with inconclusive results. We have previously shown in a meta-analysis that taking CoQ10 by patients with metabolic disorders significantly reduced serum triglycerides levels, yet did not affect other lipid profiles \[[@CR10]\]. In another meta-analysis conducted by Sahebkar et al. \[[@CR11]\], CoQ10 supplementation significantly decreased lipoprotein (a) \[Lp(a)\] levels among patients with obesity, T2DM, and CVD, mainly in those with Lp(a) ≥ 30 mg/dL. However, in another meta-analysis conducted by Suksomboon et al. \[[@CR12]\], CoQ10 supplementation had no beneficial effects on lipid profiles or blood pressures among diabetic patients.

Differences in study design, study population's characteristics, the dosage of CoQ10 used and the duration of intervention might explain the discrepancies among current evidence. We are aware of no systematic review and meta-analysis of randomized controlled trials (RCTs) on the effect of CoQ10 supplementation on lipid profiles in patients with CAD. This meta-analysis was conducted to summarize the existing evidence of RCTs to evaluate the impact of CoQ10 supplementation on lipid profiles in patients with CAD.

Methods {#Sec2}
=======

PRISMA guideline (the preferred reporting items for systematic reviews and meta-analyses) was used to design and implement this meta-analysis.

Search strategy {#Sec3}
---------------

Two independent authors (RT and MA) systematically searched online database including EMBASE, Scopus, PubMed, Cochrane Library, and Web of Science until 20th May 2018. Search words, including Mesh and text words, were applied as followed; ("chronic heart failure (CHF)" OR "CAD" OR "myocardial ischemia (MI)" OR "heart disease (HD)" OR "heart failure, diastolic" OR "CVD" OR "myocardial infarction (MI)" OR "acute myocardial infarction (AMI)" OR "cardiac disease (CD)" AND "Q10" OR "coenzyme Q10 (CoQ10)" OR "supplementation" OR "intake" AND "total cholesterol (TC)" "triglycerides (TG)" OR "low-density lipoprotein (LDL-cholesterol)" OR "LDL-C" OR "high-density lipoprotein (HDL-cholesterol)" OR "HDL-C" OR "lipoprotein(a) (Lp(a))") to identify the relevant clinical trials examining the impact of CoQ10 supplementation on lipid profiles. To avoid missing any citation that had not been captured in the primary search, the reference lists of the relevant papers and the pervious article reviews were searched by the same two researchers (RT, MA). With no time restriction, clinical trials published in English were included in this meta-analysis.

Study selection {#Sec4}
---------------

Two investigators (RT, MA) independently screened all studies, retrieved from the online database and hand-search, using a two-stage process in order to determine eligible studies for current meta-analysis. In the first stage, after reviewing the title and/or abstracts of the trials, any duplicate and non-relevant trial was removed from further process. Then, in the next stage, the full texts of related trials were retrieved to determine whether trials were potentially ideal for this meta-analysis, considering inclusion and exclusion criteria. Upon any disagreement, it was resolved by a discussion among themselves or with a third investigator (ZA or MV.J).

The following inclusion criteria was used to select eligible clinical trials for the meta-analysis: 1) being a human original RCT with parallel or crossover method; 2) study participants were patients diagnosed with heart diseases; 3) being a placebo-controlled clinical trial assessing the association between CoQ10 supplementation and lipid profiles; 4) clinical trials that reported the mean changes (SD or 95% CI) of the impact of CoQ10 on lipid profiles including total- and LDL-cholesterol, triglycerides, HDL-cholesterol, and Lp(a) at baseline and end of intervention in both intervention and placebo groups.

Animal or in-vitro trials, clinical trials without control groups, no RCT design, and any trial protocols, the congress abstracts without full text, and the studies did not meet the minimum requirement for quality assessment score were excluded from this meta-analysis.

Data extraction and quality assessment {#Sec5}
--------------------------------------

The quality assessment and data extraction from each included trial were conducted by two independent investigators (RT and MA), using Cochrane Collaboration risk of bias tool and standard Excel sheet-form 2008, respectively. Any disagreement was discussed by a third investigator (ZA or MV.J).

The following study characteristics were used to assess the quality of included trials: "randomization generation, allocation concealment, blinding of participants and outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias". The following data was extracted from each clinical trial: first author's name, year of publication, mean age, country of origin, study design, sample size (in intervention and placebo groups), duration of trial, dose of supplement, type of treatment and placebo in both intervention and control groups, the mean and SD/or 95% CI for total- and LDL-cholesterol, triglycerides, HDL-cholesterol, lipoprotein (a) concentrations at baseline and end of intervention in both intervention groups.

Statistical analyses {#Sec6}
--------------------

All statistical analyses were conducted using STATA version 12.0 (Stata Corp, College Station, TX) and Review Manager V.5.3 software (Cochrane Collaboration, Oxford, UK). The Cochran (Q) and I-squared statistics (I^2^) were applied to show the heterogeneity among included trials. Upon existing heterogeneity across trials (I^2^ ≥ 50% with *P* \< 0.05), random effects model with DerSimonian and Laird method; otherwise, fixed-effect model with inverse variance method were used to calculate the standardized mean differences (SMDs) with 95% CI considering as the pool effect size. Further, subgroup analyses were used based on pre-defined criteria such as type of disease (HF vs. CAD), type of intervention (Q10 vs. Q10 plus other nutrients), dosage of supplement (≤ 150 vs. \> 150 mg/day), duration of trial (\< 8 weeks vs. ≥8 weeks), and sample size (≤50 vs. \> 50 individuals in intervention groups) to identify the source of heterogeneity based on confounding variables.

Sensitivity analyses were conducted to specify the effect of each included trial on the pooled SMDs, using leave-one-out method. Egger's and Begg's tests were used to indicate the potential publication bias for the outcome measures. *P* \< 0.05 was considered as statistically significant.

Results {#Sec7}
=======

A total of 814 studies were identified though our initial literatures search. After screening RCTs, 8 studies were determined to be appropriate for in the present meta-analysis. The flow diagram of step by step studies identification and selection has been illustrated in Fig. [1](#Fig1){ref-type="fig"}. Seven clinical trials had double-blinded design and one of the trials was single-blinded. Seven trials were conducted using parallel design and one cross-over design. Eight RCTs reported the effects of CoQ10 supplementation on total cholesterol, 6 on LDL-cholesterol, 4 on triglycerides, 5 on HDL-cholesterol, and 3 on Lp(a). Sample size varied from 21 to 73 participants with an overall number of 267 subjects. The sample size in the placebo group was ranged from 21 to 71 with an overall number of 259 subjects. Duration of the intervention among included trials was ranged from 4 to 48 weeks. The detailed characteristics of included trials were summarized in Table [1](#Tab1){ref-type="table"}. The assessment of the methodological quality of the included trials has been indicated in Fig. [2](#Fig2){ref-type="fig"}. The findings of risk of bias assessment indicated that 6 studies were at unclear risk of bias, and 2 studies were at high risk bias based on the judgments of author.Fig. 1Literature search and review flowchart for selection of studiesTable 1Characteristics of included studiesAuthors (Ref)Publication yearSample size (control/intervention)Country/populationIntervention (name and daily dose)DurationAge (control, intervention)Presented dataBelardinelli et al. \[[@CR23]\]200621/21Italy/chronic HFCoQ10 100 mg/day4 weeks60 ± 8TC, LDL-C, TG, HDL-CDai Y et al. \[[@CR24]\]201128/28Hong Kong/left ventricular systolic dysfunctionCoQ10 300 mg/ day8 weeks65.9 ± 12.5, 59.9 ± 13.1TC, LDL-C, HDL-C, Lp(a)Mohseni et al. \[[@CR15]\]201526/26Iran/acute myocardial infarctionCoQ10 200 mg/day12 weeks48.4 ± 0.5, 47.6 ± 0.3TC, LDL-C, TG, HDL-CMirhashemi et al. \[[@CR25]\]201630/30Iran/T2DM with CADCoQ10 100 mg/day8 weeks68.9 ± 9.6Lp(a)Pourmoghaddas M et al. \[[@CR26]\]201330/32Iran/statin treated coronary heart failure patientsCoQ10 200 mg/ day16 weeks48.0 ± 8.6, 47.6 ± 8.2TC, LDL-CSingh et al. \[[@CR19]\]199922/25India/CADCoQ10 120 mg/day4 weeks50.70 ± 12.5, 54.47 ± 14.6TC, LDL-C, HDL-C, Lp(a)Singh et al. \[[@CR14]\]200371/73India/myocardial infarctionCoQ10 120 mg/day48 weeks51 ± 9,\
51 ± 10TC, LDL-C, TG, HDL-CSharifi et al. \[[@CR13]\]201731/32Iran/myocardial infarctionCoQ10 150 mg/day and L-carnitine 1200 mg/day3 months59 ± 9TC*CAD* coronary artery disease, *HDL-C* high density lipoprotein-cholesterol, *HF* heart failure, *LDL-C* low density lipoprotein-cholesterol, *Lp(a)* Lipoprotein(a), *TC* total cholesterol, *TG* triglycerides, *T2DM* type 2 diabetes mellitusFig. 2The summary of review authors' judgments about each risk of bias item for each included study

Effects of CoQ10 on lipid profiles {#Sec8}
----------------------------------

Using random-effect model, the pooled results for lipid profiles showed that CoQ10 supplementation significantly decreased total cholesterol (SMD -1.07; 95% CI, − 1.94, − 0.21, *P* = 0.01; I^2^ = 94.9%) and increased HDL-cholesterol levels (SMD 1.30; 95% CI, 0.20, 2.41, *P* = 0.02; I^2^ = 94.7%). We found no significant impact of CoQ10 supplementation on LDL-cholesterol (SMD -0.37; 95% CI, − 0.87, 0.13, *P* = 0.14; I^2^ = 82.8%) and Lp(a) (SMD -1.12; 95% CI, − 2.84, 0.61, *P* = 0.20; I^2^ = 95.7%), using random-effect model and triglycerides levels (SMD 0.01; 95% CI, − 0.22, 0.24, *P* = 0.940; I^2^ = 0.00%), using fixed-effect model (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3A-E. Meta-analysis lipid profiles standardized mean differences estimates for (**a**) total cholesterol, **b** for LDL-cholesterol, **c** for triglycerides, **d** for HDL-cholesterol and (**e**) for lipoprotein(a) in CoQ10 and control groups (CI = 95%).Total SS, total sample size

The detailed results of meta-analyses for the effects of CoQ10 on lipid profiles including total- and LDL-cholesterol, triglycerides, HDL-cholesterol, lipoprotein(a) concentrations at baseline and end of the trial in both intervention and placebo groups have been presented in Table [2](#Tab2){ref-type="table"}.Table 2Estimation of the effects of CoQ10 supplementation on lipid profiles at baseline and the end of the treatment between intervention and placebo groupsVariableNumber of studyStandardized Mean differenceCI 95%*P*-valueHeterogeneityI^2^ (%)Q*P*-value HeterogeneityTCIntervention group (after vs. before)7-1.07−1.88, − 0.260.00993.795.40\< 0.001Placebo group (after vs. before)7−0.37− 0.56, − 0.19\< 0.00142.010.340.11Change intervention group vs. placebo group8−1.07−1.94, − 0.210.01594.9138.32\< 0.001LDL-CIntervention group (after vs. before)5−0.71−1.30, − 0.120.01984.826.27\< 0.001Placebo group (after vs. before)5−0.55−1.21, 0.100.09887.331.60\< 0.001Change intervention group vs. placebo group6−0.37−0.87, 0.130.14982.829.05\< 0.001TGIntervention group (after vs. before)30.15−0.38, 0.680.59171.67.040.03Placebo group (after vs. before)3−0.09−0.34, 0.170.4930.000.310.85Change intervention group vs. placebo group40.01−0.22, 0.240.9400.002.930.40HDL-CIntervention group (after vs. before)40.54−0.07, 1.160.08182.316.930.001Placebo group (after vs. before)4−0.01− 0.24, 0.230.9640.000.350.95Change intervention group vs. placebo group51.300.20, 2.410.02194.776.05\< 0.001Lp(a)Intervention group (after vs. before)2− 0.71− 1.91, 0.500.25289.19.190.002Placebo group (after vs. before)20.02−0.37, 0.400.9290.000.170.68Change intervention group vs. placebo group3−1.12−2.84, 0.610.20495.746.96\< 0.001*HDL-C* high density lipoprotein-cholesterol, *LDL-C* low density lipoprotein-cholesterol, *Lp(a)* Lipoprotein (a); *TC* total cholesterol, *TG* triglycerides

The findings of sensitivity analyses revealed that pooled SMDs for the impact of CoQ10 on LDL-cholesterol and triglycerides were robust, and removing each trial did not affect the overall results of meta-analysis. Further, the pooled SMDs for total cholesterol was significantly different between the pre- (− 1.07; 95% CI, − 1.94, − 0.21) and post-sensitivity pooled SMD (− 0.26; 95% CI, − 0.72, 0.18) after removing Sharifi et al. \[[@CR13]\]. For HDL-cholesterol also, the pre- (1.30; 95% CI, 0.20, 2.41) and post-sensitivity pooled SMD were significantly different after excluding Singh et al. \[[@CR14]\] (1.41; 95% CI, − 0.20, 3.03) and Mohseni et al. \[[@CR15]\] (0.47; 95% CI, − 0.13, 1.09) (Table [3](#Tab3){ref-type="table"}).Table 3The assess of contribution each clinical trials in association between CoQ10 supplementation and lipid profiles based on sensitivity analysisVariablePre-sensitivity analysisUpper & lower of effect sizePost-sensitivity analysisNo. of studies includedPooled SMD (random effect)95% CIPooled SMD (random effect)95% CIExcluded studiesTC8−1.07− 1.94, − 0.21Upper−0.26− 0.72, 0.18Sharifi (b)Lower−1.30−2.29, −0.31Dai YLDL-C6−0.37−0.87, 0.13Upper−0.14− 0.42, 0.12PourmoghaddasLower−0.48− 1.04, 0.06BelardinelliTG40.01−0.22, 0.24Upper0.16−0.15, 0.48Singh (2003)Lower−0.05− 0.30, 0.19BelardinelliHDL-C51.300.20, 2.41Upper1.670.32, 3.03Dai YLower0.47−0.13, 1.09MohseniLp(a)3−1.12−2.84, 0.61Upper− 0.03−0.39, 0.33Singh (1999)Lower−1.79−4.98, 1.40Manolescu*HDL-C* high density lipoprotein-cholesterol, *LDL-C* low density lipoprotein-cholesterol, *Lp(a)* Lipoprotein (a); *TC* total cholesterol, *TG* triglycerides

Considering type of disease, the results of subgroup analysis showed a significant reduction in total cholesterol concentrations among patients with CAD (SMD -2.01; 95% CI, − 3.43, − 0.60) rather than those with HF (SMD 0.16; 95% CI, − 0.15, 0.47). Trials applying dosages ≤150 mg/day indicated greater reduction in total cholesterol levels (SMD -1.53; 95% CI, − 2.83, − 0.23) compared with the dosage of intervention \> 150 mg/day (SMD -0.52; 95% CI, − 1.78, 0.73). Moreover, compared with trials shorter than 8 weeks, total cholesterol concentrations showed greater reduction in trials with ≥8 weeks' supplementation (0.06 vs. -1.94, 95% CI: -3.33, − 0.54) (Table [4](#Tab4){ref-type="table"}). LDL-cholesterol and Lp(a) levels did not show any significant difference applying potential moderators in subgroup analyses (Table [4](#Tab4){ref-type="table"}).Table 4The effects of CoQ10 supplementation on lipid profiles with CI 95% by using subgroup analysisVariablesK^a^I^2^ (%)Q testSMD (95% CI)*P*-valueTC Total894.9138.32−1.07 (−1.94, −0.21)0.015 Type of disease  HF30.000.040.16 (−0.15, 0.47)0.306  CAD596.7122.87−2.01 (−3.43, −0.60)0.005 Type of intervention  Q10684.732.72−0.32 (−0.85, 0.22)0.244  Q10 + other299.0102.67−4.50 (−13.39, 4.39)0.321 Dosage of intervention (mg/dL)   ≤ 150596.3107.92−1.53 (−2.83, −0.23)0.021   \> 150393.430.37−0.52 (−1.78, 0.73)0.414 Duration of study   \< 8 weeks30.001.060.06 (−0.26, 0.39)0.707   ≥ 8 weeks596.9128.76−1.94 (−3.33, − 0.54)0.006 Sample size   ≤ 50 person20.000.60−0.03 (− 0.44, 0.39)0.13   \> 50 person696.3135.05−1.52 (−2.67, − 0.37)2.59LDL-C Total682.829.05−0.37 (− 0.87, 0.13)0.149 Type of disease  HF391.824.47−0.51 (−1.66, 0.64)0.387  CAD342.73.49−0.25 (− 0.61, 0.11)0.167 Type of intervention  Q10682.829.05−0.37 (− 0.87, 0.13)0.149  Q10 + other---------- Dosage of intervention   ≤ 150348.73.90−0.24 (− 0.64, 0.16)0.232   \> 150391.824.25−0.53 (−1.64, 0.57)0.344 Duration of study   \< 8 weeks340.53.36−0.12 (− 0.55, 0.30)0.568   ≥ 8 weeks391.222.64−0.62 (−1.55, 0.31)0.195 Sample size   ≤ 50 person270.03.33−0.14 (− 0.91, 0.63)0.721   \> 50 person487.824.52−0.48 (−1.17, 0.21)0.171HDL-C Total Type of disease594.776.051.30 (0.20, 2.41)0.021  HF20.000.02−0.04 (−0.43, 0.36)0.859  CAD395.948.482.28 (0.51, 4.05)0.011 Type of intervention  Q10594.776.051.30 (0.20, 2.41)0.021  Q10 + other---------- Dosage of intervention   ≤ 150378.59.290.66 (0.03, 1.30)0.041   \> 150298.566.762.58 (−2.65, 7.81)0.334 Duration of study   \< 8 weeks362.75.360.24 (−0.30, 0.78)0.387   ≥ 8 weeks297.845.293.14 (−0.96, 7.24)0.133 Sample size   ≤ 50 person271.23.480.41 (−0.39, 1.20)0.315   \> 50 person397.067.482.00 (0.06, 3.93)0.043Lp(a) Total395.746.96−1.12 (−2.84, 0.61)0.204 Type of disease  HF1--0.000.13 (−0.39, 0.66)0.621  CAD297.337.38−1.79 (−4.98, 1.40)0.272 Type of intervention  Q10395.746.96−1.12 (−2.84, 0.61)0.204  Q10 + other---------- Dosage of intervention   ≤ 150297.337.38−1.79 (− 4.98, 1.40)0.272   \> 1501--0.000.13 (−0.39, 0.66)0.621 Duration of study   \< 8 weeks297.744.27−1.64 (−5.14, 1.87)0.360   ≥ 8 weeks1--0.00−0.18 (− 0.69, 0.32)0.476 Sample size   ≤ 50 person1--0.00−3.44 (−4.36, −2.53)\< 0.001   \> 50 person20.000.72−0.03 (− 0.40, 0.33)0.866^a^ K, Number of SMD included; *CAD* coronary artery disease, *HDL-C* high density lipoprotein-cholesterol, *HF* heart failure, *LDL-C* low density lipoprotein-cholesterol, *Lp(a)* Lipoprotein(a), *TC* total cholesterol

CoQ10 supplementation significantly increased HDL-cholesterol concentrations in patients with CVD (SMD 2.28; 95% CI, 0.51, 4.05) rather than those with HF (SMD -0.04; 95% CI, − 0.43, 0.36). Considering the dosage of intervention, subgroup analysis revealed that CoQ10 doses ≤150 mg/day significantly increased HDL-cholesterol concentrations (SMD 0.66; 95% CI, 0.03, 1.30) rather than doses of \> 150 mg/day intervention (SMD 2.58; 95% CI, − 2.65, 7.81). Further, with the total sample size \> 50 participants, HDL-cholesterol levels were significantly higher (SMD 2.00; 95% CI, 0.06, 3.93) when compared to trials with ≤50 participants (SMD 0.41; 95% CI, − 0.39, 1.20). The detailed results of subgroup analyses have been summarized in Table [4](#Tab4){ref-type="table"}.

Publication bias {#Sec9}
----------------

Begg's and Egger's statistics indicated no significant evidence of publication bias for the meta-analyses evaluating the effects of CoQ10 on total cholesterol (Begg's: Z = − 0.99, *P* = 0.32 and Egger's: B = − 8.96, *P* = 0.05), LDL-cholesterol (Begg's: Z = 0.19, *P* = 0.85 and Egger's: B = − 0.51, *P* = 0.91), triglycerides (Begg's: Z = 1.07, *P* = 0.08 and Egger's: B = 2.99, *P* = 0.10), HDL-cholesterol (Begg's: Z = 0.49, *P* = 0.62 and Egger's: B = 5.31, *P* = 0.43), and Lp (a) (Begg's: Z = 0.52, *P* = 0.60 and Egger's: B = − 7.28, *P* = 0.50).

Discussion {#Sec10}
==========

The findings of current systematic review and meta-analysis showed that CoQ10 supplementation significantly improved lipid profiles by decreasing total cholesterol and increasing HDL-cholesterol levels, though did not affect triglycerides, LDL-cholesterol and Lp(a) levels in patients with CAD.

CoQ10 deficiency usually occurs with aging and may increase the risk of CVD \[[@CR9], [@CR16], [@CR17]\]. We have previously demonstrated in another meta-analysis that taking CoQ10 by patients with metabolic disorders significantly reduced serum triglycerides levels, yet did not affect other lipid profiles \[[@CR10]\]. Meta-analysis conducted by Pirro et al. \[[@CR18]\] showed that taking a nutraceutical combination of red yeast rice, berberine, policosanol, astaxanthin, CoQ10 and folic acid significantly reduced serum triglycerides, total-, LDL-and HDL-cholesterol levels. Supplementation with 200 mg/day CoQ10 for 12 weeks significantly increased HDL-cholesterol levels in hyperlipidemic patients with myocardial infarction, though did not affect other parameters of lipid profiles \[[@CR15]\]. Supplementation with 120 mg/day CoQ10 for 28 days led to similar results among patients with acute coronary disease \[[@CR19]\]. In a meta-analysis conducted by Suksomboon et al. \[[@CR12]\], total cholesterol levels significantly decreased after taking CoQ10 plus fenofibrate. The anti-hyperlipidemic effect of fenofibrate has already been proven; though its synergistic impact with CoQ10 is promising. Significant reduction in serum triglyceride levels was reported following supplementation with CoQ10 plus fenofibrate \[[@CR12]\]. However, Sahebkar et al. \[[@CR11]\] documented in their meta-analysis that CoQ10 supplementation significantly decreased plasma Lp(a) levels in individuals with lipoprotein a \[Lp(a)\] ≥30 mg/dL, though other lipid profiles parameters remained unchanged. In addition, CoQ10 administration to diabetic patients had no beneficial effects on lipid profiles and blood pressure \[[@CR12]\].

The type and different dosages of CoQ10 used are some of the possible reasons that might explain the discrepant results among previous published studies. Although the main reason CoQ10 affects lipid profiles is unknown; several mechanisms have been proposed by which CoQ10 supplements could improve lipid profiles. As an intracellular antioxidant, CoQ10 protects the cell membrane phospholipids and mitochondrial membrane protein against free radical-induced damage \[[@CR6]\]. Aldehyde derivatives from lipid peroxidation, such as malondialdehyde, inhibit lecithin-cholesterol acyl transferase (LCAT), which esterifies free cholesterol on HDL-cholesterol. So, CoQ10 can promote HDL-cholesterol production, suppress oxidative stress and subsequently reduce malondialdehyde levels \[[@CR20]\]. In addition, CoQ10 ingestion may induce gene expression of peroxisome proliferator-activated receptor-γ (PPAR-γ) through activating calcium-mediated AMPK pathway and inhibiting differentiation-induced adipogenesis \[[@CR21]\]. PPAR-γ is a nuclear receptor protein which acts as a ligand-activated transcription factor in regulating gene expression affecting insulin and lipid metabolism, differentiation, proliferation, survival and inflammation \[[@CR22]\].

Conclusions {#Sec11}
===========

CoQ10 supplementation significantly improved some of the parameters of lipid profile including total cholesterol and HDL-cholesterol levels in patients with CAD, though it might not affect the other parameters of lipid profiles. Additional prospective studies regarding the effect of CoQ10 intake on lipid profiles in patients with CAD are necessary.
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